NASDAQ
0.42USD
+0.07 (+18.35%)
We have scored 6 news catalysts on Karyopharm Therapeutics Inc. (KPTI) over the past 12 months. The biggest single-day move next to one of them came Jul 22, 2026, when KPTI closed −8.8%: “Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?”. Coverage across the window leans negative (average ticker sentiment −0.13). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
9.6M
P/E
—
EPS
—
Beta
1.04
52W range
0.31-10.99
Day range
0.36–0.43
Open
0.36
Prev close
0.36
Volume
1.5M
Avg volume
1.5M
Dividend
0.00
IPO
2013-11-06
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Karyopharm Therapeutics Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for KPTI: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
